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Background: A significant number of patients presenting for coronary revascular-
ization have chronic atrial fibrillation. Although the Cox maze III procedure is the
gold standard for the surgical treatment of this arrhythmia, few of these patients
undergo atrial fibrillation operations at the time of their coronary bypass grafting.
This study examined the long-term outcome of patients with ischemic heart disease
who underwent the Cox maze procedure at our institution.
Methods: From 1990 to 2002, 47 patients undergoing operations for ischemic heart
disease underwent a concomitant Cox maze III procedure. All patients underwent
coronary bypass grafting, and 7 (15%) patients underwent coronary bypass grafting
plus a mitral valve repair. Follow-up was performed by means of mail and telephone
questionnaires with both the patients and their cardiologists. All patients who had
any history of arrhythmia or who were taking medications had their rhythm
documented by electrocardiogram.
Results: The mean age of these patients was 62  8 years, with a marked male
predominance (45 men and 2 women). Twenty-eight (60%) of the patients had
paroxysmal atrial fibrillation, and the remainder had persistent arrhythmias. The
mean duration of atrial fibrillation was 7.6  6.5 years. The operative mortality in
this series was 2%. Nine (19%) patients required postoperative pacemakers. At last
follow-up (mean of 5.7  3.3 years), 98% of patients were free of atrial fibrillation.
Conclusion: The Cox maze III procedure has a low operative mortality and excellent
long-term efficacy in patients with ischemic heart disease. These data suggest a
more widespread use of this procedure in these patients.
The Cox maze procedure was introduced in 1987 by Dr James Cox.The final iteration of this procedure, the Cox maze III procedure, wasperformed in 1988 and since that time has been our standard oftherapy for the surgical treatment of this arrhythmia.1 The operationwas designed to interrupt the multiple macroreentrant circuits in theatria believed to be responsible for atrial fibrillation (AF). This
operation creates a maze-like series of incisions in both atria to prevent the
formation of AF. In this operation the pulmonary veins are completely isolated, and
both appendages are removed. In 2000, we modified this procedure and replaced
some of the incisions with linear lines of ablation. However, the basic lesion set has
remained unchanged. This procedure has proved to be extremely effective, with a
high success rate and the virtual elimination of late stroke.2,3 Unfortunately, the
requirement for cardiopulmonary bypass and the technical difficulty of the proce-
dure have limited its use. The recent introduction of ablation technology to simplify
From the Division of Cardiothoracic Sur-
gery, Washington University School of
Medicine at Barnes-Jewish Hospital, St
Louis, Mo.
Supported by National Institutes of Health
grants 5R01 HL32257 and T32 HR07275.
Read at the Eighty-third Annual Meeting of
The American Association for Thoracic
Surgery, Boston, Mass, May 4-7, 2003.
Received for publication May 2, 2003; re-
visions requested June 2, 2003; revisions
received June 17, 2003; accepted for pub-
lication July 7, 2003.
Address for reprints: Ralph J. Damiano, Jr,
MD, Washington University School of
Medicine, Suite 3108 Queeny Tower—
Campus Box 8234, One Barnes-Jewish
Hospital Plaza, St Louis, MO 63110 (E-
mail: damiano@msnotes.wustl.edu).
J Thorac Cardiovasc Surg 2003;126:
2016-21
Copyright © 2003 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2003 $30.00  0
doi:10.1016/j.jtcvs.2003.07.006
Surgery for Acquired Cardiovascular Disease Damiano et al
2016 The Journal of Thoracic and Cardiovascular Surgery ● December 2003
A
CD
and shorten the operation has encouraged surgeons through-
out the world to liberalize the indications for the Cox maze
procedure.
More than 500,000 patients undergo surgical revascular-
ization for ischemic heart disease every year in the United
States.4 It has been estimated that up to 15% of these
patients might have chronic or permanent AF.5 At our
institution, 1.8% of patients undergoing elective coronary
artery bypass grafting (CABG) had preoperative AF.6 Few
of these patients presently undergo a concomitant Cox maze
procedure. Unfortunately, there have been no reports exam-
ining the late results of the Cox maze procedure in this
specific group of patients that would allow surgeons to
determine whether a more widespread adoption of this
procedure is warranted. The purpose of this study was to
examine the long-term efficacy of the Cox maze procedure
in patients with ischemic heart disease undergoing coronary
bypass grafting with or without mitral valve repair for
ischemic mitral regurgitation.
Methods
From November 1990 to October 2002, 47 patients with ischemic
heart disease underwent a Cox maze procedure with CABG. Seven
patients also underwent mitral valve repair for ischemic mitral
regurgitation in addition to CABG. All patients with nonischemic
valvular heart disease were excluded from this study. This study
cohort represented 18% (74/265) of the total number of patients
who underwent a Cox maze procedure for AF at our institution
during this time period. The full lesion set of the Cox maze
procedure was performed in all cases. In each instance the patient
underwent a median sternotomy, cardiopulmonary bypass with
bicaval cannulation, and cardioplegic arrest. In the last 6 patients,
either microwave ablation (n  1) or bipolar radiofrequency
ablation (n  5) was used to replace several of the atrial lesions.
The microwave device consisted of a flexible 4-cm antenna (AFx
Inc, Fremont, Calif). The bipolar radiofrequency device had 1 mm
 5 cm electrodes mounted in the jaws of a clamp (Atricure, Inc,
Cincinnati, Ohio).
The patients’ clinical profiles and postoperative outcomes were
recorded prospectively in a computerized database. Perioperative
major complications were considered to be reoperation for bleed-
ing, prolonged ventilatory support, renal failure requiring dialysis,
mediastinitis, the placement of an intra-aortic balloon pump, peri-
operative transient ischemic attack or stroke, and perioperative
myocardial infarction. Follow-up was conducted by means of a
mailed questionnaire or telephone interview with the patient. A
review of both the referring cardiologists’ office charts and recent
electrocardiograms was obtained on all patients who stated that
they were in AF or were taking antiarrhythmic drugs or anticoag-
ulation. Information on all out-of-hospital mortality was obtained
from relatives, family physicians, and/or county death certificates.
All of the patients in this series had documented AF for a duration
longer than 6 months. Paroxysmal atrial fibrillation was defined as
intermittent AF. Persistent atrial fibrillation was defined as con-
tinuous AF. This study was approved by the Washington Univer-
sity School of Medicine/Barnes-Jewish Hospital Institutional Re-
view Board. Informed consent and permission for release of
information were obtained from each participant. The closing date
for enrolling patient data for this study was October 2002. Thus all
patients had a minimum of 6 months’ follow-up.
Late survival and outcomes were recorded and analyzed ac-
cording to the Society of Thoracic Surgeons database guidelines.
Data were collected and managed in Microsoft Access 2000 and
analyzed with SysStat version 10.0 (SPSS Corp, Chicago, Ill).
Descriptive statistics were expressed as means  SD unless oth-
erwise specified. Categoric data were expressed as counts and
proportions. Comparisons were done with paired, 2-tailed t tests
for means of normally distributed continuous variables and the
Wilcoxon rank sum test for skewed data. 2 or Fisher exact tests
were used to analyze differences among the categoric data.
Kaplan-Meier estimates were used to depict freedom from AF.
Results
Patient Demographics
The mean age of these patients was 62  8 years (range,
38-77 years). Forty-five of the patients were men, and 2
were women. There were 28 (60%) patients with paroxys-
mal AF and 10 (40%) with persistent AF. The mean pre-
operative duration of AF was 7.6  6.5 years, with a range
of 0.5 to 30 years.
In this group the indication for arrhythmia surgery was
documented stroke or transient ischemic attack in 10 (21%)
patients, medication intolerance in 4 (9%) patients, and
arrhythmia intolerance in the majority of patients (70%).
All patients underwent a Cox maze procedure with
CABG. The mean number of bypass grafts per patient was
1.8  1.0 grafts. The average ejection fraction was 50% 
14%, and 7 (28%) patients had an ejection fraction of less
than 40%.
Of this group, there were 7 patients who also underwent
mitral valve repair for ischemic mitral regurgitation. All of
these patients were treated only with a ring annuloplasty.
All patients whose mitral regurgitation was nonischemic in
origin were excluded from the study.
Perioperative Results
The average aortic crossclamp time in this series was 111
35 minutes. The mean cardiopulmonary bypass time was
204  50 minutes. The median intensive care unit stay was
3 days (range, 1-11 days), and the median total length of
stay was 11 days (range, 6-66 days). There was only one
operative mortality (2%). This patient died on postoperative
day 22 from multisystem organ failure.
In this group of patients, there was a 27% major com-
plication rate. Three (6%) patients required reoperation for
bleeding. Two patients required a postoperative intra-aortic
balloon pump. There were 2 patients who required pro-
longed ventilation (48 hours). One (2%) patient had me-
diastinitis, and there was one case of renal failure. There
were no perioperative strokes. There were 2 (4%) patients
with a documented postoperative myocardial infarction.
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The incidence of these complications was not significantly
different than that seen after isolated elective CABG (n 
1299) during the same period at our institution (Table 1).
The incidence of early postoperative atrial dysrhythmias
was 53% (25/47 patients). All of these rhythm disturbances
had resolved by the 21st postoperative day. These arrhyth-
mias were evenly split between AF and atrial flutter, and all
were transient.
A total of 9 (19%) patients required placement of a
pacemaker postoperatively. Seven (78%) of these patients
had a preoperative diagnosis of sick sinus syndrome.
Late Follow-up
Late follow-up was achieved in 45 (96%) of 47 patients.
The mean duration of follow-up was 5.7  3.3 years. There
was only one late death in the entire group of patients
treated with the Cox maze procedure with ischemic heart
disease. This patient died from lung carcinoma and was in
normal sinus rhythm. There were no late strokes in this
group. All patients were discharged from the hospital with
warfarin (Coumadin, DuPont Merck) for 2 to 3 months.
After their postoperative clinic visits for the first several
months, their medications were then managed by their re-
ferring cardiologists or family physicians. In this study 7
(16%) of the 45 patients were taking warfarin at late follow-
up.
Recurrence of AF
All patients who identified themselves as being in AF were
considered failures unless their cardiologist or an electro-
cardiogram or Holter recording documented otherwise.
There were no late recurrences of atrial flutter, and only 1
(2%) patient had recurrent AF at late follow-up. This patient
had his recurrence 10.5 years after his Cox maze procedure.
Of the entire group, 38 (84%) patients were in sinus rhythm
and completely free of antiarrhythmic drugs. Six (13%)
patients were in normal sinus rhythm but were taking anti-
arrhythmic drugs.
Overall, the Kaplan-Meier estimate for freedom from AF
for patients undergoing a Cox maze procedure and concom-
itant surgical intervention for ischemic heart disease was
100% at 10 years.
Discussion
The late results of the Cox maze procedure have been
excellent in patients with lone AF or with AF in association
with valvular heart disease.3 The long-term efficacy of this
operation in patients with ischemic heart disease in un-
known. This is pertinent information for a number of rea-
sons. First of all, there are thousands of patients undergoing
coronary revascularization each year in the United States
who have documented AF.5,6 The great majority of these
patients do not undergo a concomitant Cox maze procedure
and are thus denied a chance to cure their arrhythmia.
Second, it has been suggested that the underlying patho-
physiology responsible for the genesis of AF might be
different in patients with ischemic heart disease.7,8 Thus the
excellent results seen in other patient populations might not
be readily applicable to patients with coronary artery dis-
ease.
This study examined the long-term efficacy of the Cox
maze procedure in patients with ischemic heart disease. The
long-term success of the Cox maze procedure was excellent
in these patients. The overall freedom from AF at 10 years
was 100%. There was only one late recurrence of AF at 10.5
years. All other patients were in normal sinus rhythm or
paced atrioventricular rhythm at last follow-up. Moreover,
the great majority of these patients were no longer taking
both warfarin and antiarrhythmic drugs. With this superb
long-term cure rate and the benefits of being able to stop
warfarin, why is the Cox maze procedure so seldom per-
formed in patients with AF presenting for surgical treatment
of their coronary artery disease?
One of the principal reasons is the invasiveness and
morbidity of this procedure. However, our data would argue
for a more aggressive surgical approach. AF, antiarrhythmic
drugs, and chronic anticoagulation all have documented and
significant complications.9-11 This study demonstrated that
adding the Cox maze procedure to bypass grafting with or
without mitral valve repair in this population was associated
with a low mortality (2%), while offering the patient an
almost certain chance of cure and eliminating the risk of late
stroke. At our institution, our comparative mortality over a
similar time period for elective coronary bypass grafting
was 2.8%. The incidence of reoperation for bleeding, me-
diastinitis, and renal failure were also similar to that of the
larger population undergoing isolated elective CABG at our
institution. Although the addition of the Cox maze proce-
dure did not increase perioperative mortality, it did lengthen
hospital length of stay (median, 11 days). Our comparative
median length of stay in isolated coronary bypass grafting
during this period was 6 days.
TABLE 1. Perioperative complications
CABG/maze
(%)
Isolated CABG
(%)
P valuen  47 n  1299
Reoperation for
bleeding
6 4 1.0
Renal failure 2 6 .512
IABP 4 3 .644
Mediastinitis 2 2 .577
Stroke 0 3 .629
Myocardial infarction 4 1 .105
Operative mortality 2 3 1.0
IABP, Intra-aortic balloon pump.
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Late complications were virtually nonexistent in this
patient population. No patient had a stroke or transient
ischemic attack during the follow-up period. Impressively,
only one patient had recurrent AF in the entire group.
Moreover, the majority of patients were able to discontinue
warfarin, which carries its own long-term risk of morbidity
in these patients.
Nine (19%) patients in this study required a postopera-
tive pacemaker. The majority of these patients had a pre-
operative diagnosis of sick sinus syndrome, which is a
known risk factor for this complication. This is very similar
and not statistically significant when compared with our
overall incidence of pacemaker implantation in our recently
published series of 198 patients undergoing the Cox maze
III procedure.3
The study has limitations. There were only 47 patients in
our series. These were highly selected patients and represent
only a small fraction of all patients seen with ischemic heart
disease during this time period at Barnes-Jewish Hospital.
These patients had relatively limited coronary artery disease
and were, on the whole, low-risk healthy patients. It is
difficult to estimate the effect of this selection bias on our
results.
Another major limitation of this study was that it might
have underestimated the failure rate. Electrocardiographic
follow-up was not obtained on patients who stated that they
were in normal sinus rhythm and were not taking any
medications. However, our follow-up of all patients who
identified themselves as having any atrial dysrhythmia
should have captured the majority of treatment failures. It is
possible, though, that a patient might have had asymptom-
atic episodes of AF. Unfortunately, the logistics of contin-
uously monitoring patients for years is extremely difficult.
If patients were indeed in AF, one would have expected a
higher incidence of stroke.
In summary, the excellent long-term success rates would
argue for a more widespread adoption of the Cox maze
procedure in patients with ischemic heart disease. These
data support a policy of offering the curative Cox maze
procedure to patients with refractory permanent AF under-
going CABG. The results of other, more limited operations
in this cohort of patients is unknown and in our opinion
should only cautiously be offered to patients when there is
a well-described operation that offers an extremely high
cure rate without increasing the mortality and morbidity of
elective coronary revascularization.
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Discussion
Dr Joseph A. Dearani (Rochester, Minn). I congratulate Dr
Damiano and his colleagues for another important contribution on
the application of the Cox maze procedure for the treatment of AF,
now in patients with coronary artery disease. They have demon-
strated, in this retrospective review, that the Cox maze procedure
plus CABG can be performed with low early mortality and mor-
bidity in highly selected patients with AF and ischemic heart
disease. The need for permanent pacing was approximately 20%.
There were no late strokes, and the majority of patients were in
sinus rhythm and free of warfarin anticoagulation at late follow-up,
although electrocardiographic data were not obtained in all pa-
tients.
We, too, have had enthusiasm and success with the Cox maze
procedure. Between 1993 and 2001, 367 patients underwent the
Cox maze procedure at the Mayo Clinic, 62 of whom had con-
comitant CABG. Early mortality was 2.5%, maintenance of sinus
rhythm was greater than 90% at late follow-up, late stroke was
significantly reduced, and the need for permanent pacing was 5%.
These favorable results have encouraged us to make an effort to
apply the Cox maze procedure to many more patients with AF who
undergo operations for another cardiac diagnosis.
I believe the important issue with the subject of AF and
coronary artery disease is patient selection. The authors make
reference and comparison to 1299 patients who underwent isolated
coronary bypass surgery during the same time interval. What
percentage of these 1299 patients also had AF and did not have the
maze procedure and why? The average number of bypass grafts in
your review was only 1.8. Specifically, how many patients had
symptomatic coronary artery disease (eg, angina, dyspnea, or heart
failure) that was the indication for coronary bypass surgery versus
those scheduled for a maze operation and found incidentally to
have coronary disease on preoperative angiography that required 1
or 2 grafts?
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You noted in your article that “late complications were virtu-
ally nonexistent” in your patient population. The majority of the
patients in your review had normal ventricular function, but no
information was provided about comorbidity, such as diabetes or
renal, pulmonary, or peripheral vascular disease. Late complica-
tions in patients with significant ischemic heart disease are well
documented and are not nonexistent.
How did you select these patients for a concomitant maze
procedure, and when would you simply just ligate the left atrial
appendage? Would you have avoided doing the maze procedure in
any of the patients who had postoperative complications or death?
Numerous groups have documented the safety and efficacy of
the Cox maze procedure. What is the place of the newer, costly
disposable devices? These devices were used in some of your
patients. You state in your conclusions, however, that these newer
devices and techniques should only “cautiously be offered.” Did
any of the late complications or mortality that occurred happen in
any of these patients?
In principle, it appears attractive to apply the traditional maze
procedure to many different cardiac diagnoses during the course of
cardiac operations. As an advocate of the maze procedure, I do
believe it should be offered to relatively healthy patients with
coronary disease, good left ventricular function, and few comor-
bidities. However, in the current era, we are confronted more and
more with challenging patients who require coronary revascular-
ization or redo procedures or who have decreased left ventricular
function, renal insufficiency, obstructive lung disease, the frequent
use of multiple and powerful antiplatelet agents, older age, et
cetera. I believe wider application of the maze procedure to all
patients with ischemic heart disease will result in greater operative
risk. What is your message to practicing surgeons for this group of
patients?
I agree that the maze procedure has earned wider applicability
in properly selected patients. Although the procedure decreases the
incidence of stroke, I do not believe it eliminates the risk of stroke
in this group of patients. In addition, I disagree with the conclusion
in your article that it should be a policy to offer the traditional Cox
maze procedure to all patients undergoing coronary bypass surgery
at this time. Newer devices in the future, if proved effective, might
allow more widespread application of the technique.
Dr Damiano. Thank you, Dr Dearani, and those are excellent
comments. First of all, I agree completely with you. This is a very
selected series and a relatively small series of patients, and I think
you cautiously should draw large conclusions regarding the entire
universe of patients coming for CABG.
First of all, the incidence of AF in patients coming for elective
coronary bypass grafting at our institution is 1.8%. Interestingly, in
the Cleveland Clinic the number of patients was just under 1%.
Therefore it is a relatively small number of total patients. How-
ever, if you look nationwide, we are dealing with thousands of
patients who do present with chronic AF. No patient was consid-
ered for a Cox maze procedure at our institution unless they had
AF for at least 6 months. All of these patients met the standard
indication for the Cox maze procedure of drug failure, arrhythmia
intolerance, or both, with a small subset, as I said, having neuro-
logic complications. These patients represented a relatively small
percentage of the total patients with AF who underwent CABG at
our institution during this time period.
You have to remember that this is our entire experience dating
back to the very early days of the Cox maze procedure. In the
beginning of this experience, we were hesitant to widely apply it
in patients, particularly those having extensive other concomitant
procedures. Obviously this is a selected group, and you can see,
compared with our overall group of patients having coronary
revascularization, that this group had significantly fewer distal
grafts per patient. Only time will tell what the results will be with
a more aggressive application of the Cox maze procedure in this
group of patients.
I do believe that the use of newer ablation devices, which have
comprised our more recent experience, has led us to be signifi-
cantly more aggressive. In this series our only death occurred in a
patient having a traditional cut-and-sew Cox maze procedure rel-
atively early in the experience. We have had no recent deaths or
major complications in the patients in whom we have used the
ablation devices. With these ablation devices, we have been able to
cut more than 30 minutes off the crossclamp time required to
perform the Cox maze procedure.
I certainly do not want to say that the addition of the Cox maze
procedure does not add potential morbidity. All of us would agree
that these are relatively long crossclamp and bypass times. Al-
though these have been improving recently, if we did a much
larger series, we might have seen a higher complication rate.
However, our data do show that the operative mortality is
similar to that with isolated CABG, and we have looked at our
major complications with the Society of Thoracic Surgeons data-
base. Even with the fact that most of these patients underwent a
lengthy traditional cut-and-sew Cox maze procedure, we still did
not see a higher incidence of complications, albeit with this very
selected group.
We do believe that with the newer ablation devices and the fact
that this now adds only 10 or 15 minutes to our crossclamp time
that we should be more aggressive in offering this operation to
patients with chronic AF. There are some tremendous long-term
benefits. Even if there was a slightly higher short-term morbidity,
the ability to get these patients off warfarin and to maintain sinus
rhythm would be a tremendous benefit.
As far as our current indications, we do consider patients at
reasonable risk undergoing elective coronary bypass grafting to be
candidates for a concomitant Cox maze procedure. Time will tell,
and we will certainly have more numbers in the next 5 years with
this more aggressive policy. We can then look at the question of
whether we might be seeing more complications in this group.
Recently, there has been much interest around the world in
simplifying and decreasing the number of the incisions of the Cox
maze procedure. This study does represent long-term follow-up of
the entire lesion set, whether done surgically or with an ablation
device. Our data reveal that if this entire lesion set is performed,
you can expect more than a 90% cure rate at 10 years.
The reason we looked at this particular group of patients was
that it appears from recent experimental work that the cause of AF
might be very different in patients with ischemic heart disease than
in either those with valvular heart disease or with lone AF. Actu-
ally, I would have predicted that this group would have had a
worse outcome because you would consider that they would prob-
ably have recurrent ischemic heart disease during follow-up. How-
ever, the long-term results were excellent.
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Dr Paul A. Kurlansky (Miami Beach, Fla). I congratulate you
on a very provocative and beautifully performed study. As you
know from the AFFIRM study, which randomized patients with
chronic AF to either rate control or rhythm control, absolutely no
difference in late mortality was found. In fact, there was a sug-
gestion that there was higher stroke-related morbidity in the
rhythm control group and that was hypothesized to be perhaps
because the patients who were in sinus rhythm were intermittently
in AF and had cerebrovascular events or cerebroembolic events at
that time. But it also raised the possibility that perhaps this sub-
group of patients who have AF require chronic anticoagulation,
even after they are converted to sinus rhythm.
Your study, which had a zero stroke rate at follow-up both at 5
and 10 years is extremely revealing in this regard in that it suggests
that even in this subgroup of patients with AF, once they are in
sinus rhythm, at least with this procedure, they no longer have a
need for anticoagulation, which is an extremely valuable contri-
bution in and of itself.
A certain percentage of patients were receiving anticoagulation,
and therefore I have 2 questions. What were the indications for the
anticoagulation in those patients who were receiving it? For the
patients who were not receiving anticoagulation, were they receiv-
ing any form of treatment (eg, Plavix or antiplatelet agents) other
than the aspirin that they would normally receive for having
coronary artery disease?
Dr Damiano. Thank you, and those are excellent questions. In
terms of our indications for anticoagulation, virtually none of these
patients were under our own care. Most of these were referred
from around the country, around the world, and anticoagulation
was based solely on the discretion of their referring physician.
Some referring physicians maintained chronic anticoagulation, and
we do not have information on their rationale. We just recorded
which patients were receiving anticoagulation. Whether it was
appropriate I can not tell you. Most of the patients were taking
aspirin. As far as other antiplatelet drugs, I do not have that
information, but it would be interesting to look it up.
Actually, when we presented the full Cox maze III experience
last year, these patients virtually never had a stroke. In our whole
series, since the Cox maze III procedure was introduced in 1998,
we have only seen one late stroke, and that patient had a cerebral
atrioventricular malformation. Obviously, that is probably a testi-
mony to the fact that this operation is very good at maintaining
sinus rhythm. It might also be due to the fact that we ligate the left
atrial appendage.
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